British Columbia Investment Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.96M | Sell |
15,568
-3,795
| -20% | -$477K | 0.01% | 588 |
|
|
2025
Q1 | $2.14M | Buy |
19,363
+34
| +0.2% | +$3.76K | 0.01% | 605 |
|
|
2024
Q4 | $2.64M | Buy |
19,329
+2,543
| +15% | +$347K | 0.02% | 578 |
|
|
2024
Q3 | $1.93M | Sell |
16,786
-2,270
| -12% | -$262K | 0.01% | 615 |
|
|
2024
Q2 | $2.62M | Buy |
19,056
+7,326
| +62% | +$1.01M | 0.02% | 552 |
|
|
2024
Q1 | $1.62M | Buy |
11,730
+497
| +4% | +$68.5K | 0.01% | 613 |
|
|
2023
Q4 | $1.48M | Buy |
11,233
+2,444
| +28% | +$322K | 0.01% | 617 |
|
|
2023
Q3 | $989K | Hold |
8,789
| – | – | 0.01% | 638 |
|
|
2023
Q2 | $829K | Buy |
8,789
+230
| +3% | +$21.7K | 0.01% | 696 |
|
|
2023
Q1 | $866K | Buy |
8,559
+144
| +2% | +$14.6K | 0.01% | 682 |
|
|
2022
Q4 | $1.01M | Sell |
8,415
-919
| -10% | -$110K | 0.01% | 620 |
|
|
2022
Q3 | $991K | Sell |
9,334
-1,633
| -15% | -$173K | 0.01% | 648 |
|
|
2022
Q2 | $1.07M | Sell |
10,967
-3,678
| -25% | -$359K | 0.01% | 684 |
|
|
2022
Q1 | $1.37M | Sell |
14,645
-1,955
| -12% | -$183K | 0.01% | 728 |
|
|
2021
Q4 | $1.41M | Sell |
16,600
-887
| -5% | -$75.6K | 0.01% | 764 |
|
|
2021
Q3 | $1.68M | Buy |
17,487
+136
| +0.8% | +$13K | 0.01% | 731 |
|
|
2021
Q2 | $1.69M | Buy |
17,351
+2,820
| +19% | +$275K | 0.01% | 756 |
|
|
2021
Q1 | $1.41M | Sell |
14,531
-435
| -3% | -$42.3K | 0.01% | 740 |
|
|
2020
Q4 | $1.43M | Sell |
14,966
-335
| -2% | -$32.1K | 0.01% | 734 |
|
|
2020
Q3 | $1.47M | Buy |
15,301
+1,251
| +9% | +$120K | 0.01% | 672 |
|
|
2020
Q2 | $1.71M | Buy |
14,050
+4,479
| +47% | +$546K | 0.02% | 594 |
|
|
2020
Q1 | $828K | Sell |
9,571
-10,930
| -53% | -$946K | 0.01% | 616 |
|
|
2019
Q4 | $2.2M | Buy |
+20,501
| New | +$2.2M | 0.02% | 652 |
|